Gecacitinib 100mg BiD vs PBO in active r-axSpA: Met primary endpt ASAS40 at wk 16 showing efficacy of gecacitinib vs. PBO (51.9%vs12.9%,p<0.0001) Gecacitinib showed ⬆️ improvements in ASDAS-CRP, physical fnxn, spinal mobility & QOL Promising tx. AbsOP0240 @RheumNow #EULAR2026 https://t.co/FytoRgxvnG